Matching Items (2)
Filtering by

Clear all filters

151860-Thumbnail Image.png

Lead identification, optimization and characterization of novel cancer treatment strategies using repositioned drugs

Description
Cancer is the second leading cause of death in the United States and novel methods of treating advanced malignancies are of high importance. Of these deaths, prostate cancer and breast cancer are the second most fatal carcinomas in men and women respectively, while pancreatic cancer is the fourth most fatal…

Cancer is the second leading cause of death in the United States and novel methods of treating advanced malignancies are of high importance. Of these deaths, prostate cancer and breast cancer are the second most fatal carcinomas in men and women respectively, while pancreatic cancer is the fourth most fatal in both men and women. Developing new drugs for the treatment of cancer is both a slow and expensive process. It is estimated that it takes an average of 15 years and an expense of $800 million to bring a single new drug to the market. However, it is also estimated that nearly 40% of that cost could be avoided by finding alternative uses for drugs that have already been approved by the Food and Drug Administration (FDA). The research presented in this document describes the testing, identification, and mechanistic evaluation of novel methods for treating many human carcinomas using drugs previously approved by the FDA. A tissue culture plate-based screening of FDA approved drugs will identify compounds that can be used in combination with the protein TRAIL to induce apoptosis selectively in cancer cells. Identified leads will next be optimized using high-throughput microfluidic devices to determine the most effective treatment conditions. Finally, a rigorous mechanistic analysis will be conducted to understand how the FDA-approved drug mitoxantrone, sensitizes cancer cells to TRAIL-mediated apoptosis.
ContributorsTaylor, David (Author) / Rege, Kaushal (Thesis advisor) / Jayaraman, Arul (Committee member) / Nielsen, David (Committee member) / Kodibagkar, Vikram (Committee member) / Dai, Lenore (Committee member) / Arizona State University (Publisher)
Created2013
165106-Thumbnail Image.png

Pulse Sequence Programming for Magnetic Resonance Imaging: Deuterium Imaging and Glioblastoma Detection

Description
Glioblastoma brain tumors are among the most lethal human cancers. Treatment efforts typically involve both surgical tumor removal, as well as ongoing therapy. In this work, we propose the use of deuterium magnetic resonance imaging (MRI) to delineate tumor boundaries based on spatial distributions of deuterated leucine, as well as…

Glioblastoma brain tumors are among the most lethal human cancers. Treatment efforts typically involve both surgical tumor removal, as well as ongoing therapy. In this work, we propose the use of deuterium magnetic resonance imaging (MRI) to delineate tumor boundaries based on spatial distributions of deuterated leucine, as well as resolve the metabolism of leucine within the tumor. Accurate boundary identification contributes to effectiveness of tumor removal efforts, while amino acid metabolism information may help characterize tumor malignancy and guide ongoing treatment. So, we first examine the fundamental mechanisms of deuterium MRI. We then discuss the use of spin-echo and gradient recall echo sequences for mapping spatial distributions of deuterated leucine, and the use of single-voxel spectroscopy for imaging metabolites within a tumor.
ContributorsCostelle, Anna (Author) / Beeman, Scott (Thesis director) / Kodibagkar, Vikram (Committee member) / Barrett, The Honors College (Contributor) / Department of Physics (Contributor) / School of Mathematical and Statistical Sciences (Contributor)
Created2022-05